Adjuvant S-1 Sustains Survival Benefit at 5 Years in Biliary Cancer

The ASCOT phase III trial's prespecified 5-year follow-up analysis reports that adjuvant S-1 after resection of biliary tract cancer produced a 5-year overall survival of 64% versus 52% with observation (HR, 0.72; 95% CI, 0.55 to 0.95), with median OS of 8.2 versus 5.9 years. The trial states relapse-free survival also favored S-1 and that treatment effects were generally consistent across subgroups, concluding the findings confirm a sustained survival benefit supporting S-1 as a standard adjuvant treatment.

Most relevant for: Patients who have undergone surgical resection for biliary tract cancer and are being considered for adjuvant therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.